TC-P 262Selective P2X3, P2X2/3 antagonist CAS# 873398-67-5 |
- Nadifloxacin
Catalog No.:BCC4804
CAS No.:124858-35-1
- Calcipotriol monohydrate
Catalog No.:BCC1445
CAS No.:147657-22-5
- Halobetasol Propionate
Catalog No.:BCC4664
CAS No.:66852-54-8
- Dihydroartemisinin
Catalog No.:BCN6264
CAS No.:71939-50-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 873398-67-5 | SDF | Download SDF |
| PubChem ID | 59598765 | Appearance | Powder |
| Formula | C14H18N4O | M.Wt | 258.32 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO | ||
| Chemical Name | 5-(5-methyl-2-propan-2-ylphenoxy)pyrimidine-2,4-diamine | ||
| SMILES | CC1=CC(=C(C=C1)C(C)C)OC2=CN=C(N=C2N)N | ||
| Standard InChIKey | RAKSAPLZNJXYRB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C14H18N4O/c1-8(2)10-5-4-9(3)6-11(10)19-12-7-17-14(16)18-13(12)15/h4-8H,1-3H3,(H4,15,16,17,18) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Selective P2X3 and P2X2/3 receptor antagonist (pIC50 values are 7.39 and 6.68 respectively). Displays no detectable activity at P2X1, P2X2, P2X4 and P2X7 receptors (pIC50 < 4.7). |
TC-P 262 Dilution Calculator
TC-P 262 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.8712 mL | 19.3558 mL | 38.7117 mL | 77.4234 mL | 96.7792 mL |
| 5 mM | 0.7742 mL | 3.8712 mL | 7.7423 mL | 15.4847 mL | 19.3558 mL |
| 10 mM | 0.3871 mL | 1.9356 mL | 3.8712 mL | 7.7423 mL | 9.6779 mL |
| 50 mM | 0.0774 mL | 0.3871 mL | 0.7742 mL | 1.5485 mL | 1.9356 mL |
| 100 mM | 0.0387 mL | 0.1936 mL | 0.3871 mL | 0.7742 mL | 0.9678 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 1,7-Dihydroxy-4-methoxyxanthone
Catalog No.:BCN7602
CAS No.:87339-76-2
- Ramipril
Catalog No.:BCC5012
CAS No.:87333-19-5
- AIM-100
Catalog No.:BCC1333
CAS No.:873305-35-2
- IKK-16 (IKK Inhibitor VII)
Catalog No.:BCC4555
CAS No.:873225-46-8
- Ganoderone A
Catalog No.:BCN2448
CAS No.:873061-79-1
- Ivacaftor (VX-770)
Catalog No.:BCC2478
CAS No.:873054-44-5
- 3,29-Dibenzoyl karounitriol
Catalog No.:BCN2717
CAS No.:873001-54-8
- 6-Aminouracil
Catalog No.:BCC8768
CAS No.:873-83-6
- 3-Methoxyoxohernandaline
Catalog No.:BCN8107
CAS No.:872729-34-5
- 1,2,3,10-Tetramethoxy-9-(2-hydroxy-4,5-dimethoxybenzyloxy)oxoaporphine
Catalog No.:BCN8120
CAS No.:872729-33-4
- Dabigatran etexilate mesylate
Catalog No.:BCC1511
CAS No.:872728-81-9
- MEDICA 16
Catalog No.:BCC7956
CAS No.:87272-20-6
- Fortuneine
Catalog No.:BCN6401
CAS No.:87340-25-8
- Triangularine
Catalog No.:BCN2051
CAS No.:87340-27-0
- PU-H71
Catalog No.:BCC1872
CAS No.:873436-91-0
- Lupeolic acid
Catalog No.:BCN6520
CAS No.:87355-32-6
- GDC-0152
Catalog No.:BCC2252
CAS No.:873652-48-3
- Demethylcarolignan E
Catalog No.:BCN7018
CAS No.:873694-46-3
- Omecamtiv mecarbil
Catalog No.:BCC3710
CAS No.:873697-71-3
- PLX647
Catalog No.:BCC6370
CAS No.:873786-09-5
- TATU
Catalog No.:BCC2822
CAS No.:873798-09-5
- BMS-599626 Hydrochloride
Catalog No.:BCC1426
CAS No.:873837-23-1
- Fidaxomicin
Catalog No.:BCC4660
CAS No.:873857-62-6
- 3,4,5'-Trimethoxy-3',4'-methylenedioxy-7,9':7',9-diepoxylignan
Catalog No.:BCN7238
CAS No.:873867-94-8
Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model.[Pubmed:21410458]
Br J Pharmacol. 2011 Jul;163(6):1315-25.
BACKGROUND AND PURPOSE: P2X3 and P2X2/3 receptors are highly localized on the peripheral and central pathways of nociceptive signal transmission. The discovery of A-317491 allowed their validation as chronic inflammatory and neuropathic pain targets, but this molecule has a very limited oral bioavailability and CNS penetration. Recently, potent P2X3 and P2X2/3 blockers with a diaminopyrimidine core group and better bioavailability were synthesized and represent a new opportunity for the validation of P2X3-containing receptors as targets for pain. Here we present a characterization of three representative diaminopyrimidines. EXPERIMENTAL APPROACH: The activity of compounds was evaluated in intracellular calcium flux and electrophysiological recordings from P2X receptors expressed in mammalian cells and in a in vivo model of inflammatory pain (complete Freund's adjuvant (CFA) in rat paws). KEY RESULTS: Compound A potently blocked P2X3 (pIC(50)= 7.39) and P2X2/3 (pIC(50)=6.68) and showed no detectable activity at P2X1, P2X2, P2X4 and P2X7 receptors (pIC(50)< 4.7). Whole-cell voltage clamp electrophysiology confirmed these results. Compounds showed good selectivities when tested against a panel of different classes of target. In the CFA model, compound B showed significant anti-nociceptive effects (57% reversal at 3mg.kg(-1) ). CONCLUSIONS AND IMPLICATIONS: The diaminopyrimidines were potent and selective P2X3 and P2X2/3 receptor antagonists, showing efficacy in vivo and represent useful tools to validate these receptors as targets for inflammatory and neuropathic pain and provide promising progress in the identification of therapeutic tools for the treatment of pain-related disorders.
